MUC1 and breast carcinoma: The significance of MUC1 as a relevant therapeutic target is highlighted by its atypical expression in > 64% of carcinomas diagnosed annually, and in over 90% of breast carcinomas irrespective of hormone or growth factor receptor status [14].